InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the complete record of transactions filed by OrbiMed Genesis Master Fund, L.P.. Director active across 1 company, notably Enliven Therapeutics, Inc.. Aggregated, 2 disclosures have been recorded. History available since 15 June 2026. The latest transaction was filed on 22 June 2026 (Notice of proposed sale (Form 144)). Regulator: SEC (Form 4). All data is free.
2 of 2 declarations